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Multiply Activated VLP






What is Cell-Free Biology?
The Reproduction, Study, and Use of Complex 








A New Biological World
• No Need to Maintain a Living Cell
• Now a Stable, Accessible Catalytic System
• Can Integrate and FOCUS Metabolism
cytoplasm C FG A C FG H
Michael Jewett
Another view of Cell-free Biology:
Scalable, Controllable Bioprocessing
Traditional Bioprocesses are Converted to 
Homogenous (or Heterogeneous) Catalysis
Sutro Biopharma, Inc. of
South San Francisco
Has Demonstrated Production
of Pharmaceutical Quality GMCSF 
with 100 Liter Cell-Free Reactions
Note:  I am a Founder and Shareholder
 700 mg/l in 10 hr
 2 column purification
 20µl rxns are predictive
HA-Head 
HBc VLP
















• Three types: A, B and C
• Type A viruses are the most virulent 
human pathogens, classified into 
16 HA subtypes (H1–H16) and 9 NA 
subtypes (N1–N9)
• Current types circulating in human: 
H1N1, H3N2 and B-type viruses
 The most effective way to
protect against flu virus
infection is vaccination.
 HA is the most abundant
protein on the viral coat and
is highly immunogenic. So HA
has been the primary vaccine
antigen for last 40 years.
http://www.cdc.gov/flu/images.htm 6
Influenza virus
Influenza (flu) virus is the cause of major respiratory illness in humans.
Endocytosis
Schematic diagram of the influenza viral life cycle
G Neumann et al. Nature 459, 931-939 (2009)
Progeny virions
7






Either more stable HA head domain or conserved HA stem domain
(Daian C. Ekiert et. Al. 2009)
• Most antibodies bind to the Head domain
• The head domain is compact, and can fold 
much more readily than the stem domain.
Differences Between different HA 
















• The Stem domain is conserved, so it 
might be broadly protective against 



















Elicit strong immune responses
Either more stable HA head domain or conserved HA stem domain
Native Hemagglutinin




This scenario is especially
relevant for seasonal




















components can be 
produced throughout 
the year.
Only the antigens are 











































Cell-Free Technology Can Conserve Capital and
Still Enable RAPID Responses
Assume Routine Pharmaceutical Production Target of 100 kg/year
Need about 1250 liters of cell broth for extract per day
Use Continuous Culture; D = 0.7 hr -1
Requires One 100-liter Fermentor
For Growing Cells for Extract
Need  about 200,000 liters of cell-free reaction
Assume 3 runs per day -- 200 days per year
Requires One 350-liter Cell-Free Reactor
Now, assume we suddenly need 500 million doses
of 5 µg each = 2.5 kg of antigen
Assuming 200 mg/L Purified Yields, 
Need 12,500 Liters of Cell-free Reaction
Need 14 days to Produce the Antigen !!
Potential Therapeutic Vaccine for Lymphoma:











VLP Vaccine Anti-tumor Activity
<28 Days
Expect positive, protective anti-idiotype 
immune response in most patients.




Released and Stored in Inventory
Cell-free Manufacturing Enables Fast 
Delivery and High Quality at Low Cost
• Fast, reliable production




3-6 Days 3-5 Days 1-2 weeks
Antigen: Id
1. Express Id




2. LC & HC genes
















































Note: Thin Film Reactions were Used for 1 ml Scale-up
Bundy et al., Biotech & Bioeng 100:28-37; 2008
Particles
per ml
MS2 VLP from CFPS* HepB Core VLP from CFPS*
Electron Microscopy Indicates Uniform Spherical Particles
*CFPS = Cell-Free Protein Synthesis
Bundy et al., Biotech & Bioeng 100:28-37; 2008




























Murine Immune Responses to VLP Lymphoma Vaccines





























L Serum anti-Id IgG2a &b Conc.
Co-attached Stimulants are beneficial
HBcore Scaffolding is More Effective than MS2
VLP Surface Display Can Stimulate Strong IgG2 Responses






















Mice Were Challenged with IV Injection of 38C13 Lymphoma (200 cells)
0.0%
20.0%


















Wei Chan, Patrick Ng, Ron Levy, Shoshana Levy
Best Protection from VLP (HepBc + antigen + GMCSF + CpG)
Goals
Side view













Elicit strong immune responses
Native Hemagglutinin






































John Welsh, Yuan Lu






Fetuin (from fetal bovine serum) : Molecular weight: 48.4 kDa; pI: 3.2 - 3.8








Foldon * Protein concentration based on monomer.
• Expected Binding Affinity

















Elicit strong immune responses
Native Hemagglutinin
Design of HA stem domains
Influenza A virus (A/California/07/2009 (H1N1)
Purple: HA1;  Blue: HA2;  Green: Disulfide bond
Red: linker or other peptides   Orange: Foldon






• Molecular weight: 31782.5 (Stem-his)
• Expression plasmid: PY71 (T7 promoter)
• Total 4 disulfide bonds in stem domains
Foldon
6×His













Load 1 ml of denatured protein
solution on Ni-NTA column
Wash the column with 5 column 
volumes of Denaturing Wash
Buffer
Dialyze against Refolding Buffer with 6M
urea for 24hrs at 4°C
Dialyze against Refolding Buffer with 4M
urea for 24hrs at 4°C
1ml CFPS products







Initial Multi-Step Solubilization and Refolding Protocol
Elute the column with 5 column 
volumes of Denaturing Elution
Buffer
Examine the purity by SDS-PAGE 
and measure the protein 
concentration
Dilute purified proteins to about
50μg/ml
Dialyze against Refolding Buffer with 2M
urea for 24hrs at 4°C
Dialyzie against Refolding Buffer for 24hrs at
4°C
Dialyzie against final Dialysis Buffer for
24hrs at 4°C
Wash inclusion body pellets 3 times with
Wash Buffer I and 3 times with Wash 
Buffer II
Dissolve washed inclusion bodies in
Denaturing Washi Buffer by adding 5 mM
DTT and votex-shaking






Purple: HA1;  Blue: HA2;  
Yellow: Hydrophobic residues
Mutation of exposed hydrophobic domains
L174D
Influenza virus A/California/07/2009 (H1N1)
Purple: HA1;  
Blue: HA2;  
Green: Disulfide bond






























Green:  HA1   
Cyan:    HA2   
Red:     Mutation sites 
S-S bond 
Linker
Original design (8 Cys) New design (5 Cys)
New design with CT (4 Cys)
Yuan Lu
1     2
Invitrogen gel: MOPS-SDS 
running buffer (pH7.7)













Dramatically decreased no. of intermolecular S-S bonds after decreasing no. of Cysteines
Wanted to stabilize trimer during  Conjugation and Administration
To keep trimer stable on VLPs and in mouse studies
S-S Create artificial S-S bonds in Foldon
H-bond topology of the trimeric 
foldon β-hairpin propeller
A: G10-D17 B: R8-D17 C: R8-G18
D: P7-G18 E: A12-K16 F: Y13-R15
Yuan Lu














Sample and running buffer: 50mM Tris-HCl; 100mM Arginine; 0.05% Brij35; pH=8
All protein sample: 1.5 μg 






• B, C and E all can form the trimer with intermolecular S-S bond between Foldon proteins.
• E was the best.








Loading 1 ml of denatured protein
solution on Ni-NTA column
Washing the column with 3
volumes of Denaturing Washing
Buffer
Eluting the column with 3 volumes
of Denaturing Elution Buffer
Diluting 10X rapidly in Refolding 
Buffer, putting in anearobic
glove box for 10 min, and then 
leaving at 4oC for 24 hours
Dialyzing against Dialysis Buffer
for 12 hrs at 4oC
1ml CFPS products
Centrifugation (14,000rpm for 15min)
and discarding the supernatant
Washing inclusion body pellets 3
times with Washing Buffer I and 3 
times with Washing Buffer II
Dissolving Purification Refolding
Simplified Purification and Refolding Procedure
Centrifugation
Examining the purity by SDS-PAGE
Diluting purified proteins to about
50μg/ml
-- Concentrating
-- Checking by SDS-PAGE &SEC
Dissolving washed inclusion bodies in
Denaturing Washing Buffer by
sonication and adding 5mM DTT
Centrifugation (14,000rpm for 15min)
for discarding still insoluble fragments
•Washing buffer I: 50mM Tris-HCl; 100mM NaCl; 1mM EDTA; pH=8
•Washing buffer II: 100mM NaH2PO4; 10mM Tris-HCl; 20mM Imidazole; pH=8
•Denaturing washing buffer: 8M Urea; 100mM NaH2PO4; 10mM Tris-HCl; 20mM Imidazole; 1mM DTT; pH=8
•Denaturing elution buffer: 8M Urea; 100mM NaH2PO4; 10mM Tris-HCl; 250mM Imidazole; 1mM DTT; pH=8
•Refolding buffer: 50mM Tris-HCl; 600mM Arginine; 2mM EDTA; Cystamine/Cysteamine (0.5:5mM); 0.05% Brij35; pH=8
•Dialysis buffer: 50mM Tris-HCl; 100mM Arginine; 0.05% Brij35; pH=8
Centrifugation
Yuan Lu
Mutations to stabilize HA Stem trimer plus optimized refolding
M        1           2  
M: Protein standard
1: Wild-type HA Stem trimer






Note: After protein refolding
TrimerAggregates Monomer
Newly designed stabilized HA-Stem proteins 

















1 437 µg 362 µg 83% ≈70%




2 392 µg 319 µg 81% ≈75%
3 448 µg 344 µg 77% ≈76%
Ave. 426µg  ± 30µg 342µg ± 22µg 80 ± 3% 74 ± 3%





No. C179 for ELISA 
(Neutralizing Ab)
than full-length HA.
≈ 40 × higher apparent 
affinity
Apparent Kd ≈ 0.4 nM
The starting antigen concentrations were the same 6 µg/ml. Yuan Lu
H173*D174*
Attach HA stem to VLPs (Initial Experiment)
nnAA site
✔
A: H173*;  B: D174*; C: G301*
A: H173*;  
B: D174*; 
C: G301*







Need to improve the click 
reaction conditions
?












































935 mg/l FliC 50 14.5
3.4 g/l HepB 5 16.7
5mM TTMA 5 409
25mM Tetrakis Cu (I) 0.5 205
1% Tween 20 0.6 80











Flagellin on VLPs is approx. 10× more bioactive
Yuan Lu






 Can enable very rapid responses to pandemic threats
 Enables co-attachment of immune response stimulators 
to increase the efficacy of VLP vaccines
Modular VLP Vaccine Design and Cell-free Technology:
42
 Enables production of functional HA Head and Stem Trimers
 Allows antigens and stimulators to be arrayed and properly
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